Published 9 days ago • loading... • Updated 9 days ago

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Summary by biopharmadive.com

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.

1 Articles

All

Left

Center

Right

biopharmadive.com

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.

9 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated8 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in 9 days ago on Friday, February 14, 2025.

Sources are mostly out of (0)

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

1 Articles

1 Articles

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics